Repligen (RGEN) Jefferies Global Healthcare Conference summary

Leadership insights and company strengths

• Emphasis on innovation and rapid R&D as key differentiators, with a broadening product portfolio opening new opportunities.

• Company size enables agility and strong customer-centricity, supporting tailored solutions and responsiveness.

Financial metrics and growth outlook

• Book-to-bill ratio improved from 0.85 to 1.03 over the past 18 months, signaling a positive shift in order trends.

• Focus is shifting from book-to-bill as a leading indicator to sustained order growth and execution of the growth plan.

• Long-term growth is expected to outpace the market, driven by innovation, market share gains, and a broadening portfolio.

Commercial strategy and key accounts

• Expansion of key account management, now covering 21 major accounts, is enabling deeper penetration and multi-product sales.

• Enhanced access to decision makers in both pharma and CDMO segments is accelerating growth and traction.